Latest Lorcaserin Stories
In the briefing documents for the May 10th, 2012 meeting of the FDA Advisory Committee, reviewers expressed concerns on safety of Lorcaserin obesity drug. Safety concerns relate mainly to heart problems. Another obesity drug, the popular Fen Phen, was withdrawn from the market in 1997. Fen Phen was linked with heart valve damage and primary pulmonary hypertension (PPH). The most insidious part of Fen Phen and heart valve damage is that many people who took Fen Phen are just now...
A panel voted 18 to 4 in favor of approving the new anti-obesity drug Lorcaserin for use on the drug market. The drug works to control the appetite through receptors in the brain, and a study showed it helped nearly half of participants lose up to five percent of their body weight. The Food and Drug Administration is scheduled to decide on June 27 whether the drug should be approved for use in the U.S. Lorcaserin was rejected by the Endocrinologic and Metabolic Drugs Advisory...
SAN DIEGO and WOODCLIFF LAKE, N.J., May 10, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the lorcaserin marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. Lorcaserin is an investigational drug candidate intended for weight management. In addition to the United States, the territories in the expanded agreement now include most of...
SAN DIEGO and WOODCLIFF LAKE, N.J., May 10, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 18 to 4, with one abstention, that the available data demonstrate that the potential benefits of lorcaserin outweigh the potential risks when used long-term in a population of overweight and obese individuals. Lorcaserin is an investigational...
SAN DIEGO, May 1, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the first quarter ended March 31, 2012, and reviewed recent developments. "Lorcaserin has the potential to provide a new treatment option for the medical management of obesity," said Jack Lief, Arena's President and Chief Executive Officer. "We are focused on preparing for the May 10 advisory committee meeting for lorcaserin, and look forward to discussing the...
SAN DIEGO, March 26, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid...
SAN DIEGO, March 14, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the fourth quarter and full year ended December 31, 2011, and reviewed recent developments. "Lorcaserin has the potential to be an important option for physicians to address the medical management of obesity, helping patients lose weight and improve their overall cardiometabolic health," said Jack Lief, Arena's President and Chief Executive Officer. "We look forward to...
SAN DIEGO, March 8, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will report fourth quarter and full year 2011 financial results after the NASDAQ Global Select Market closes on Wednesday, March 14, 2012. That same afternoon, Arena's President and Chief Executive Officer, Jack Lief, will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results for the fourth quarter and full year 2011 and to...
SAN DIEGO, March 2, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the filing of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition. Arena expects...
The makers of three previously rejected weight loss drugs have resubmitted their products to the Food and Drug Administration (FDA) for approval, with each hoping to become the first new prescription anti-obesity drug to be approved in the U.S. in 13 years. As previously reported here on RedOrbit.com, one of those three drugs, Qnexa, received approval from a panel of FDA advisors on Thursday by a 20-2 margin. That verdict placed Qnexa, a combination of the appetite suppressant...
